Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide

Patent metadata

Field	Value
Publication number	US-9365637-B2
Application number	US-201113579529-A
Country	US
Kind code	B2
Filing date	Feb 21, 2011
Priority date	Feb 19, 2010
Publication date	Jun 14, 2016
Grant date	Jun 14, 2016

Abstract

The present invention provides: a novel antiviral agent containing a human antibody κ light chain, a novel human abzyme containing a human antibody κ light chain; a polynucleotide, a vector, and a transformant, encoding a human antibody κ light chain of the above; a primer set for effectively obtaining a human antibody κ light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set.

First claim

The invention claimed is:

1. A human abzyme comprising one of the following (a) through (f):
(a) a human antibody kappa (κ) light chain with a variable domain consisting of SEQ ID NO: 26, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 24;
(b) a human antibody kappa (κ) light chain with a variable domain consisting of SEQ ID NO: 14, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1;
(c) a human antibody kappa (κ) light chain with a variable domain consisting of SEQ ID NO: 50, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48;
(d) a human antibody kappa (κ) light chain with a variable domain consisting of SEQ ID NO: 35, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33;
(e) a human antibody kappa (κ) light chain with a variable domain consisting of SEQ ID NO: 54, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52; or
(f) a human antibody kappa (κ) light chain with a variable domain consisting of SEQ ID NO: 22, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20.

2. The human abzyme as set forth in claim 1 , wherein:
the human abzyme has an anti rhabdovirus activity, and anti influenza virus activity; and
the variable domain consists of SEQ ID NO: 26,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20.

3. The human abzyme as set forth in claim 1 , wherein:
the human abzyme has an anti rhabdovirus activity, anti influenza virus activity, and cytotoxicity against cancer cells; and
the variable domain consists SEQ ID NO: 14,
the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1.

4. The human abzyme as set forth in claim 1 , wherein:
the human abzyme has an anti influenza virus activity and nucleolytic activity; and
the variable domain consists of SEQ ID NO: 50,
the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48.

5. The human abzyme as set forth in claim 1 , wherein:
the human abzyme has an anti influenza virus activity; and
the variable domain consists of SEQ ID NO: 35,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33.

6. The human abzyme as set forth in claim 1 , wherein:
the human abzyme has an anti influenza virus activity; and
the variable domain consists of SEQ ID NO: 54,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52.

7. The human abzyme as set forth in claim 1 , wherein:
the human abzyme has an anti rhabdovirus activity; and
the variable domain consists of SEQ ID NO: 22,
the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20.

8. A method for treating a patient of a rhabdovirus infectious disease by administering a human abzyme comprising a human antibody kappa (κ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 30, or 22 to the patient, wherein the administering does not comprise administering a human antibody heavy chain.

9. A method for treating a patient of an influenza virus infectious disease by administering a human abzyme comprising a human antibody kappa (κ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 50, 35 or 54 to the patient.

Assignees

• Uda Taizo
• Hifumi Emi
• Nishizono Akira
• Arakawa Mitsue
• Japan Science & Tech Agency

Inventors

• Uda Taizo
• Hifumi Emi
• Nishizono Akira
• Arakawa Mitsue

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• C07K2317/30

  characterized by aspects of specificity or valency · CPC title

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title